Phytonadione - Generic Drug Details
What are the generic drug sources for phytonadione and what is the scope of patent protection?
Phytonadione
is the generic ingredient in five branded drugs marketed by Pai Holdings Pharm, Roche, Alembic, Amneal, Baxter Hlthcare Corp, Caplin, Cipla, Dr Reddys, Gland, Glaxosmithkline, Intl Medication, Lupin, Orbicular, Sunny, Hospira, Bausch, Amneal Pharms Co, Hikma, Novax, Sciegen Pharms, Tp Anda Holdings, and Zydus Lifesciences, and is included in twenty-eight NDAs. Additional information is available in the individual branded drug profile pages.Thirty-three suppliers are listed for this compound.
Summary for phytonadione
| US Patents: | 0 |
| Tradenames: | 5 |
| Applicants: | 21 |
| NDAs: | 27 |
| Finished Product Suppliers / Packagers: | 30 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 7 |
| Patent Applications: | 5,048 |
| Drug Prices: | Drug price trends for phytonadione |
| What excipients (inactive ingredients) are in phytonadione? | phytonadione excipients list |
| DailyMed Link: | phytonadione at DailyMed |
Recent Clinical Trials for phytonadione
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Australasian Kidney Trials Network | Phase 3 |
| Waitemata District Health Board | Phase 3 |
| Salford Royal NHS Foundation Trust | Phase 3 |
Pharmacology for phytonadione
| Drug Class | Vitamin K Warfarin Reversal Agent |
| Physiological Effect | Increased Prothrombin Activity Reversed Anticoagulation Activity |
US Patents and Regulatory Information for phytonadione
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | MEPHYTON | phytonadione | TABLET;ORAL | 010104-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Intl Medication | PHYTONADIONE | phytonadione | INJECTABLE;INJECTION | 083722-001 | Approved Prior to Jan 1, 1982 | AB1 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Amneal | PHYTONADIONE | phytonadione | INJECTABLE;INJECTION | 217734-001 | Jun 1, 2026 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Gland | PHYTONADIONE | phytonadione | INJECTABLE;INJECTION | 217386-001 | Dec 10, 2024 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch